EP Biocomposites (543595)

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 14.28% suggests the company is generating a reasonable return on invested capital despite its small scale.
• Latest quarter sales of ₹4 crore show the business still has an operating revenue base.
• P/E of 16.54 is not absurd if earnings stabilise, though recent profit decline makes it risky.
• Market cap of ₹29 crore leaves scope for growth if operations can be revived.

Concerns

• Profit growth is down 57.14%, and latest net profit is effectively ₹0 crore—earnings power has vanished.
• Sales growth is negative at -7.50%, indicating a shrinking top line.
• Piotroski F-Score of 3/9 points to weak financial health.
• No dividend, no book value, no debt/equity, no promoter holding data—cannot assess margin of safety or management alignment.

AI Analysis

What do I see in EP Biocomposites? A ₹29 crore microcap in waste management, priced at ₹174.20, sitting at the top of its 52-week range. Graham taught me to weigh the figures before the story. ROCE of 14.28% is reasonable, but the income statement is deteriorating: sales are down 7.50%, and profits have collapsed by 57.14%. The latest quarter says it all—sales of ₹4 crore and net profit of ₹0 crore. The company is barely breaking even. At a P/E of 16.54, I am being asked to pay sixteen times earnings for a shrinking earnings base. That is not value; that is hope. The Piotroski F-Score of 3 out of 9 confirms poor fundamental health. There is no dividend, so my only reward must come from a genuine business recovery. Yet I cannot even complete a normal balance-sheet check: no book value, no debt/equity ratio, no ROE, no promoter holding data. Without these, any intrinsic value calculation is guesswork. If this were truly a turnaround situation, I would want proof: a return to positive quarterly profit, sales growth turning up, and an F-Score improving from 3. And I would want it at a price leaving room for error. At the 52-week high, with profit gone and data missing, the margin of safety is absent. I will pass until the numbers show more than a stock price.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer